GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Low-dose aspirin helps reduce the incidence of major cardiovascular event among diabetic individuals

People with Type 2 diabetes (T2D) and an elevated risk for cardiovascular disease (CVD) who took low-dose aspirin were less likely to experience a major cardiovascular event, including heart attack, stroke or death, than people with T2D at similar CVD risk who did not take low-dose aspirin, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025.

3 Nov 2025

Healthy lifestyle habits plus GLP-1 RA drugs can improve heart health of people with Type 2 diabetes

People with Type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including heart attack, stroke or cardiovascular disease death, compared to people only taking the medication, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025.

3 Nov 2025

WHO reviews highlight limited long-term data on GLP-1 drug safety

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.

30 Oct 2025

Diabetes remission possible with GLP-1 drugs, Italian study confirms

In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, depending on how remission was defined. The most pragmatic definition (Remission 3) was linked to improved glycemia, weight, and a lower risk of microvascular and cardiovascular events.

29 Oct 2025

Exploring the gut-brain-immune axis in neurodegeneration

Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), represent a growing global health burden, particularly in aging populations.

28 Oct 2025

AI-powered app matches human-led programs in diabetes prevention

Researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report that an AI-powered lifestyle intervention app for prediabetes reduced the risk of diabetes similarly to traditional, human-led programs in adults.

27 Oct 2025

Semaglutide protects the heart beyond weight loss, SELECT trial shows

Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in people with overweight or obesity and cardiovascular disease. Early waist reduction explained only a third of this benefit, showing that semaglutide’s heart protection extends beyond fat loss.

26 Oct 2025

Semaglutide can offer important heart benefits that go beyond weight loss

A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight loss and diabetes management) – confirms it also lowers the risk of major heart problems in people who are overweight or obese and already have heart disease, even if they don't have diabetes.

23 Oct 2025

A new car vs. health insurance? Average family job-based coverage hits $27K

With the federal shutdown entering its fourth week, spurred by a stalemate over the cost of health insurance for 22 million Americans on Affordable Care Act plans, a new report shows that over 154 million people with coverage through an employer also face steep price hikes — and that the situation is likely to get worse.

22 Oct 2025

Exercise can mitigate depression-like behaviors induced by high-fat, high-sugar diets

Researchers led by Professor Yvonne Nolan at University College Cork have identified specific metabolic pathways through which exercise counteracts the negative behavioral effects of consuming a Western-style cafeteria diet.

21 Oct 2025

GLP-1 drugs like Ozempic may slow how quickly alcohol hits the bloodstream

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and intoxication in obese individuals.

17 Oct 2025

New enzyme offers cleaner route to more stable diabetes and obesity drugs

Chemistry researchers at the University of Utah have uncovered an enzyme, dubbed PapB, that can "tie off" therapeutic peptides-protein-like drugs-into tight rings, a process known as macrocyclization.

16 Oct 2025

GLP-1 medications found to slow alcohol absorption and lessen intoxication

There's mounting evidence that popular drugs prescribed for diabetes management and weight loss - better known by trade names like Ozempic and Wegovy - could be effective in reducing alcohol use.

15 Oct 2025

In Mississippi, Medicaid coverage of weight loss drugs fails to catch on

April Hines has battled with her weight since she was a teenager. But in the past couple of years, she's fallen from 600 pounds to 385, and her blood pressure and blood sugar levels are down, too. "I'm not as fatigued as I used to be, and I've been able to go back to church," she said.

15 Oct 2025

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.

9 Oct 2025

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.

7 Oct 2025

Study finds surge in the use of weight loss drugs among bariatric surgery patients

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and Type 2 diabetes.

3 Oct 2025

Prediabetes can go into remission without weight loss

Research shows up to 22% of prediabetic individuals achieve remission without weight loss, emphasizing metabolic health over weight loss in diabetes prevention.

2 Oct 2025

Study shows prediabetes remission does not always require weight loss

Remission of prediabetes can occur even without weight loss, protecting against type 2 diabetes in up to 22% of individuals. Metabolic improvements, healthier fat distribution, and enhanced β-cell function, not body weight change, drive this benefit.

30 Sep 2025

Cannabidiol shows promise for obesity and metabolic syndrome

Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models of obesity and metabolic syndrome. However, human evidence is still limited, highlighting the need for rigorous trials before clinical use.

29 Sep 2025

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Low-dose aspirin helps reduce the incidence of major cardiovascular event among diabetic individuals

Healthy lifestyle habits plus GLP-1 RA drugs can improve heart health of people with Type 2 diabetes

WHO reviews highlight limited long-term data on GLP-1 drug safety

Diabetes remission possible with GLP-1 drugs, Italian study confirms

Exploring the gut-brain-immune axis in neurodegeneration

AI-powered app matches human-led programs in diabetes prevention

Semaglutide protects the heart beyond weight loss, SELECT trial shows

Semaglutide can offer important heart benefits that go beyond weight loss

A new car vs. health insurance? Average family job-based coverage hits $27K

Exercise can mitigate depression-like behaviors induced by high-fat, high-sugar diets

GLP-1 drugs like Ozempic may slow how quickly alcohol hits the bloodstream

New enzyme offers cleaner route to more stable diabetes and obesity drugs

GLP-1 medications found to slow alcohol absorption and lessen intoxication

In Mississippi, Medicaid coverage of weight loss drugs fails to catch on

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

Study finds surge in the use of weight loss drugs among bariatric surgery patients

Prediabetes can go into remission without weight loss

Study shows prediabetes remission does not always require weight loss

Cannabidiol shows promise for obesity and metabolic syndrome

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in